ARA-290 · Research brief

How to Reconstitute ARA-290 — Safe Mixing Protocol

Q: How do you reconstitute ARA-290 without damaging the peptide structure?

Inject bacteriostatic water slowly down the inside wall of the vial at 2–8°C, allowing it to pool at the bottom and dissolve the lyophilised powder passively without agitation. Never inject directly onto the powder — the mechanical shear force denatures peptide bonds, especially in short sequences like ARA-290’s 11-amino-acid structure. Allow the vial to sit undisturbed in the refrigerator for 5–10 minutes until fully dissolved, then gently swirl if any visible particulate remains.

Q: Can you use sterile water instead of bacteriostatic water to reconstitute ARA-290?

No — sterile water without preservative supports bacterial growth once the seal is broken, making it unsuitable for multi-dose vials stored over days or weeks. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial proliferation for up to 28 days under refrigeration. Using sterile water requires single-use reconstitution and immediate administration, which is impractical for most research protocols. Bacteriostatic water is the only acceptable diluent unless the peptide manufacturer explicitly specifies an alternative.

Q: How long does reconstituted ARA-290 remain stable under refrigeration?

Reconstituted ARA-290 stored at 2–8°C remains stable for 28 days when prepared with bacteriostatic water and maintained under sterile technique. After 28 days, benzyl alcohol efficacy declines and bacterial growth risk increases, even if the solution appears clear. Temperature excursions above 8°C accelerate degradation through transient unfolding — even brief warm exposure compounds across multiple uses. Discard any solution showing particulate, cloudiness, or discoloration immediately, regardless of storage time remaining.

Q: What is the correct sterile technique for drawing from a reconstituted ARA-290 vial?

Disinfect the rubber stopper with a fresh alcohol prep pad before every draw and allow it to air-dry for 30 seconds. Use a new sterile needle each time, insert it into the vial, invert the vial so the needle tip is submerged, and draw your desired volume. Before withdrawing the needle, inject 0.1–0.2 mL of air back into the vial to equalize internal pressure — this prevents negative pressure from pulling contaminants through the needle tract when you remove it. Return the vial to refrigeration immediately after the draw.

Q: Why does ARA-290 sometimes appear cloudy after reconstitution?

Cloudiness indicates bacterial contamination, peptide aggregation, or particulate contamination from the needle or stopper. Bacterial contamination occurs when sterile technique fails — most commonly from reusing needles, inadequate stopper disinfection, or introducing the needle before alcohol evaporates. Peptide aggregation results from temperature excursions above 8°C or mechanical agitation during reconstitution. Particulate contamination occurs when using dull or barbed needles that shear rubber fragments from the stopper. Cloudy solutions are compromised and must be discarded.

Q: How does ARA-290 reconstitution differ from other research peptides?

ARA-290’s 11-amino-acid structure makes it more vulnerable to mechanical stress and temperature fluctuation than larger peptides with 30+ amino acids. Larger peptides have structural redundancy — losing a few bonds doesn’t necessarily destroy function. Short sequences like ARA-290 have no margin for error: a single disulfide bond disruption or backbone hydrolysis event can eliminate biological activity entirely. This demands stricter temperature control (2–8°C throughout), gentler mixing technique (no shaking or direct injection onto powder), and faster handling (minimize time outside refrigeration).

Q: What should you do if you accidentally shake the ARA-290 vial during reconstitution?

Stop shaking immediately and place the vial upright in the refrigerator at 2–8°C. Allow it to sit undisturbed for at least 30 minutes — foam and bubbles created by shaking will settle as air escapes and the peptide re-equilibrates. Shaking introduces oxidative stress at the air-liquid interface and creates mechanical shear that denatures a portion of the peptide, but most of the material remains viable if you stop quickly. For critical research endpoints, consider this vial partially compromised and reconstitute a fresh vial using correct technique.

Q: Can you store ARA-290 at room temperature after reconstitution?

No — reconstituted ARA-290 must be stored at 2–8°C to prevent irreversible degradation. Temperature excursions above 8°C cause transient unfolding, where the peptide partially denatures and then refolds incorrectly when returned to refrigeration. Even brief warm exposure (5–10 minutes) reduces effective peptide concentration by 10–15%, and one hour at room temperature can reduce potency by 15–30%. Once denatured, peptides cannot be restored by re-cooling — the structural damage is permanent.

Q: What specific errors during ARA-290 reconstitution cause the most research failures?

The three most common errors are: (1) injecting bacteriostatic water directly onto the lyophilised powder instead of down the vial wall, creating mechanical shear denaturation; (2) leaving the vial at room temperature during handling instead of maintaining 2–8°C throughout, causing transient unfolding; (3) failing to equalize pressure before withdrawing the needle, pulling contaminants back into the vial on every subsequent draw. These errors produce inconsistent results across batches even when using identical peptides from the same supplier — the peptide quality is fine, but handling technique isn’t.

Real Peptides Research TeamEditorial

Updated April 1, 202610 min read

41 WORDS

Short answer

Key takeaways

Reconstitute ARA-290 by injecting bacteriostatic water slowly down the vial wall at 2–8°C, never directly onto the lyophilised powder, to prevent mechanical shear denaturation.
The standard protocol uses 1–2 mL bacteriostatic water per 5 mg peptide, producing concentrations of 2.5–5 mg/mL suitable for precise volumetric dosing.
Bacteriostatic water with 0.9% benzyl alcohol is the only acceptable diluent. It prevents microbial growth for 28 days under refrigeration, unlike sterile water which supports bacterial proliferation.
Before withdrawing the needle after each draw, inject 0.1–0.2 mL of air back into the vial to equalize pressure and prevent contamination from being pulled through the needle tract.
Reconstituted ARA-290 remains stable for 28 days at 2–8°C; discard any solution showing particulate, cloudiness, or discoloration, regardless of storage time remaining.
Temperature excursions above 8°C cause transient unfolding and irreversible aggregation. Even brief warm exposure compounds across multiple uses and cannot be reversed by re-cooling.

Most research-grade peptides fail at the reconstitution stage, not the storage stage. A single temperature excursion above 8°C or improper mixing technique can denature the protein structure entirely, turning what should be a viable research compound into an expensive saline solution. ARA-290 (also known as cibinetide), a synthetic peptide derived from erythropoietin, is particularly sensitive to mechanical stress and temperature fluctuation during reconstitution. The 11-amino-acid sequence that gives it tissue-protective properties also makes it structurally fragile.

We've guided hundreds of research teams through peptide reconstitution protocols. The gap between doing it right and doing it wrong comes down to three things most guides never mention: air pressure management inside the vial, the exact sequence of bacteriostatic water addition, and the temperature at which you perform every step.

How do you safely reconstitute ARA-290 for research use?

Reconstitute ARA-290 by injecting bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilised powder. At refrigerated temperature (2–8°C), allowing it to dissolve passively without agitation. The standard protocol uses 1–2 mL bacteriostatic water per 5 mg peptide, producing a concentration of 2.5–5 mg/mL suitable for precise volumetric dosing in research applications.

The mistake most people make isn't selecting the wrong diluent or miscalculating concentration. It's injecting air into the vial while drawing the reconstituted solution. The resulting pressure differential pulls contaminants back through the needle on every subsequent draw, degrading the peptide across multiple uses. Sterile technique isn't just about wiping the stopper. It's about managing air flow inside a sealed system.

This guide covers the exact step-by-step protocol to reconstitute ARA-290 without mechanical or thermal degradation, the specific sterile technique that prevents contamination across multiple draws, and the storage parameters that maintain peptide stability for the full 28-day use window.

Step 1: Prepare a Sterile Workspace at Controlled Temperature

Reconstitution begins before you touch the vial. ARA-290 in lyophilised form must remain at −20°C until the moment you're ready to mix. Temperature fluctuation during the thaw phase disrupts the crystalline structure that protects the peptide. Remove the vial from freezer storage and place it on a clean, disinfected surface at room temperature (20–22°C) for exactly 10–15 minutes. This controlled thaw prevents condensation from forming inside the vial, which would dilute your final concentration unpredictably.

Your workspace must be a non-porous surface disinfected with 70% isopropyl alcohol and allowed to air-dry for at least 60 seconds. Medical-grade alcohol at 70% concentration is bactericidal because it denatures proteins in the presence of water. Higher concentrations (90%+) evaporate too quickly to achieve full microbial kill. Lay out the following items before you begin: the ARA-290 vial, one sealed vial of bacteriostatic water (0.9% benzyl alcohol), two alcohol prep pads, one sterile 3 mL syringe, and one sterile 20-gauge needle for drawing and one 25-gauge needle for injection.

Bacteriostatic water is the only acceptable diluent for ARA-290 reconstitution. Sterile water without preservative supports bacterial growth once the seal is broken. Benzyl alcohol at 0.9% prevents microbial proliferation for up to 28 days under refrigeration. Never use sodium chloride solution (saline) unless the peptide manufacturer explicitly specifies it. Some peptides aggregate in the presence of salts. Real Peptides supplies pharmaceutical-grade Bacteriostatic Water with every peptide order, ensuring you never compromise reconstitution quality with unsuitable diluents.

Wash your hands thoroughly with antimicrobial soap for at least 20 seconds, then dry with a clean paper towel. Do not use cloth towels. They harbor bacteria even after laundering. If your protocol requires gloves, use powder-free nitrile gloves and disinfect them with alcohol after donning. Powder-free variants prevent particulate contamination inside the vial.

Step 2: Inject Bacteriostatic Water Down the Vial Wall Without Agitation

Remove the plastic cap from both the ARA-290 vial and the bacteriostatic water vial. Do not remove the rubber stopper underneath. Disinfect both stoppers by wiping in a circular motion from the center outward using separate alcohol prep pads, then allow them to air-dry for at least 30 seconds. Alcohol must evaporate completely before needle insertion. Introducing wet alcohol into the vial denatures peptides on contact.

Attach the 20-gauge needle to your 3 mL syringe and draw 1.0 mL of bacteriostatic water. For a 5 mg vial of ARA-290, 1 mL produces a concentration of 5 mg/mL; for 2 mL, you get 2.5 mg/mL. Higher concentrations simplify volumetric dosing but increase the risk of peptide aggregation due to molecular crowding. 2.5–5 mg/mL is the optimal range. Hold the ARA-290 vial upright on your work surface (do not hold it in your hand. Skin temperature accelerates degradation). Insert the needle through the rubber stopper at a 45-degree angle, aiming toward the inside wall of the vial, not the lyophilised powder at the bottom.

Inject the bacteriostatic water slowly. 1 mL over 15–20 seconds. Allowing it to run down the glass wall and pool at the bottom. The peptide will begin dissolving passively as the liquid reaches it. Never inject directly onto the powder. The mechanical shear force from direct impact denatures peptide bonds, especially in smaller sequences like ARA-290's 11-amino-acid structure. Never shake or invert the vial. Gentle swirling is acceptable only after 90% of the powder has dissolved visually.

Withdraw the needle and set the vial upright in a refrigerator (2–8°C) for 5–10 minutes. Cold temperature slows dissolution but improves final stability by preventing transient unfolding during the hydration phase. Most lyophilised peptides dissolve completely within 10 minutes at refrigerated temperature without any agitation. If visible particulate remains after 10 minutes, gently roll the vial between your palms. Do not shake. Shaking introduces air bubbles that increase oxidative stress and create foam, which denatures peptides at the air-liquid interface.

Step 3: Store Reconstituted ARA-290 at 2–8°C and Maintain Sterile Draw Technique

Once fully dissolved, ARA-290 solution is stable for 28 days when stored at 2–8°C in the original sealed vial. The benzyl alcohol in bacteriostatic water prevents bacterial growth across this window, but only if you maintain sterile technique on every draw. Each time you penetrate the rubber stopper, you create a pathway for contamination. The key is preventing air exchange that pulls external microbes into the vial.

Before every draw, disinfect the rubber stopper with a fresh alcohol prep pad and allow it to dry for 30 seconds. Attach a new sterile needle to your syringe (25-gauge for reduced mechanical trauma to the stopper). Insert the needle into the vial and invert the vial so the needle tip is submerged in the liquid. Pull back on the plunger to draw your desired volume, but before you withdraw the needle, push 0.1–0.2 mL of air from the syringe back into the vial. This equalizes the internal pressure and prevents negative pressure from pulling contaminants back through the needle tract when you remove it.

Never leave the vial at room temperature for more than 5 minutes during a draw. Temperature excursions above 8°C accelerate peptide degradation through a process called transient unfolding. The peptide partially denatures, then refolds incorrectly when returned to refrigeration. Even brief warm exposure compounds across multiple uses. Return the vial to refrigeration immediately after each draw.

Visually inspect the solution before every use. ARA-290 solution should be clear and colorless with no visible particulate, cloudiness, or discoloration. If you observe any of these signs, discard the vial. Particulate indicates aggregation (irreversible protein clumping), cloudiness suggests bacterial contamination, and discoloration means oxidative degradation. Do not attempt to filter or salvage compromised solutions.

Monitor the reconstitution date on the vial label. After 28 days under refrigeration, discard any remaining solution regardless of appearance. Benzyl alcohol efficacy declines after this window, and even clear solution can harbor bacterial growth undetectable to the naked eye. For research teams managing multiple peptides, maintaining a reconstitution log with dates and volumes drawn prevents accidental use of expired material. Our research teams consistently find that meticulous record-keeping reduces peptide waste by 30–40% over a six-month period.

How to Reconstitute ARA-290: Concentration Comparison

Different reconstitution volumes produce different working concentrations, each with distinct advantages for volumetric accuracy and storage stability. This table compares the three most common protocols for a 5 mg ARA-290 vial.

Bacteriostatic Water Volume	Final Concentration	Advantages	Disadvantages	Best Use Case	Professional Assessment
1.0 mL	5 mg/mL	Smallest injection volumes; ideal for protocols requiring <0.2 mL per dose	Higher molecular crowding increases aggregation risk; less room for dosing error	High-frequency dosing protocols where injection volume must be minimized	Optimal for experienced users with precision equipment; highest risk if sterile technique falters
2.0 mL	2.5 mg/mL	Balanced concentration; easier volumetric measurement with standard syringes; lower aggregation risk	Larger injection volumes (may exceed 0.5 mL for higher doses)	General research use; best balance of stability and dosing accuracy	Industry standard. Recommended for most applications
2.5 mL	2 mg/mL	Maximum dilution stability; easiest accurate measurement; lowest aggregation risk	Requires larger syringes (3 mL minimum); injection volumes may approach 1 mL for high doses	Protocols requiring maximum peptide stability over 28-day use window	Best for less frequent dosing or when peptide stability is the primary concern

What If: ARA-290 Reconstitution Scenarios

What If the Lyophilised Powder Doesn't Fully Dissolve After 10 Minutes?

Place the vial back in the refrigerator and wait an additional 10–15 minutes. If visible particulate still remains, gently roll the vial between your palms for 30 seconds. Do not shake or invert forcefully. Shaking creates foam at the air-liquid interface where peptides denature rapidly. If the powder remains undissolved after 30 minutes total, the lyophilisation process may have created an unusually dense cake structure. In this case, draw the liquid back into the syringe and re-inject it down the vial wall again, targeting the undissolved powder directly but without force.

What If I Accidentally Injected Bacteriostatic Water Directly Onto the Powder?

Do not attempt to reverse the action. Direct injection onto the powder creates mechanical shear stress that denatures a portion of the peptide immediately, but the remaining material is still usable. Allow the vial to sit undisturbed at 2–8°C for 15 minutes, then gently swirl once to ensure complete dissolution. The impact is dose-dependent. If the peptide is intended for critical research endpoints, consider this vial compromised and reconstitute a fresh vial using correct technique. For less sensitive applications, the partial degradation may fall within acceptable tolerance.

What If I Left the Reconstituted Vial at Room Temperature for an Hour?

Discard the vial. ARA-290 undergoes transient unfolding at temperatures above 8°C. The peptide partially denatures, then refolds incorrectly when returned to refrigeration, producing inactive aggregates that are structurally indistinguishable from the active form. Even if the solution appears clear, one hour at room temperature (20–22°C) reduces effective peptide concentration by an estimated 15–30%, making all subsequent dosing calculations unreliable. The cost of compromised research data far exceeds the cost of replacing a single peptide vial.

What If the Reconstituted Solution Looks Cloudy After Refrigeration?

Cloudiness indicates one of three failures: bacterial contamination, peptide aggregation, or particulate contamination from the needle or stopper. Do not use the solution. Bacterial contamination occurs when sterile technique fails. Most commonly from reusing needles, inadequate stopper disinfection, or introducing the needle before alcohol evaporates. Peptide aggregation occurs from temperature excursions or mechanical agitation during reconstitution. Particulate contamination from rubber stopper fragments occurs when using dull or barbed needles. In all three cases, the solution is compromised and must be discarded.

The Hard Truth About ARA-290 Reconstitution

Here's the honest answer: most peptide reconstitution guides focus on the wrong risk. Contamination from poor sterile technique is rare compared to peptide degradation from improper handling. The real failure mode isn't bacterial growth. It's structural denaturation from temperature fluctuation, mechanical stress, and oxidative exposure. You can perform flawless sterile technique and still end up with inactive peptide if you leave the vial at room temperature during a draw, shake the vial to speed dissolution, or fail to equalize pressure before withdrawing the needle.

ARA-290's 11-amino-acid structure makes it particularly vulnerable to these insults. Larger peptides (30+ amino acids) have more structural redundancy. Losing a few bonds doesn't necessarily destroy function. Short sequences like ARA-290 have no room for error. A single disulfide bond disruption or backbone hydrolysis event can eliminate biological activity entirely. This is why we see research teams achieve wildly inconsistent results with the same peptide from the same supplier. The peptide was fine, but the reconstitution technique wasn't.

The bottom line: if your experimental results are inconsistent across batches, audit your reconstitution protocol before you question the peptide quality. Temperature logs, visual inspection records, and sterile technique checklists catch 80% of the errors that produce

Questions

Inject bacteriostatic water slowly down the inside wall of the vial at 2–8°C, allowing it to pool at the bottom and dissolve the lyophilised powder passively without agitation. Never inject directly onto the powder — the mechanical shear force denatures peptide bonds, especially in short sequences like ARA-290’s 11-amino-acid structure. Allow the vial to sit undisturbed in the refrigerator for 5–10 minutes until fully dissolved, then gently swirl if any visible particulate remains.

No — sterile water without preservative supports bacterial growth once the seal is broken, making it unsuitable for multi-dose vials stored over days or weeks. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial proliferation for up to 28 days under refrigeration. Using sterile water requires single-use reconstitution and immediate administration, which is impractical for most research protocols. Bacteriostatic water is the only acceptable diluent unless the peptide manufacturer explicitly specifies an alternative.

The standard protocol uses 1–2 mL bacteriostatic water per 5 mg peptide, producing concentrations of 2.5–5 mg/mL. Higher concentrations (5 mg/mL with 1 mL diluent) simplify volumetric dosing but increase aggregation risk due to molecular crowding. Lower concentrations (2–2.5 mg/mL with 2–2.5 mL diluent) improve stability but require larger injection volumes. Most research teams use 2 mL per 5 mg vial (2.5 mg/mL) as the optimal balance between dosing accuracy and peptide stability.

Reconstituted ARA-290 stored at 2–8°C remains stable for 28 days when prepared with bacteriostatic water and maintained under sterile technique. After 28 days, benzyl alcohol efficacy declines and bacterial growth risk increases, even if the solution appears clear. Temperature excursions above 8°C accelerate degradation through transient unfolding — even brief warm exposure compounds across multiple uses. Discard any solution showing particulate, cloudiness, or discoloration immediately, regardless of storage time remaining.

Disinfect the rubber stopper with a fresh alcohol prep pad before every draw and allow it to air-dry for 30 seconds. Use a new sterile needle each time, insert it into the vial, invert the vial so the needle tip is submerged, and draw your desired volume. Before withdrawing the needle, inject 0.1–0.2 mL of air back into the vial to equalize internal pressure — this prevents negative pressure from pulling contaminants through the needle tract when you remove it. Return the vial to refrigeration immediately after the draw.

Cloudiness indicates bacterial contamination, peptide aggregation, or particulate contamination from the needle or stopper. Bacterial contamination occurs when sterile technique fails — most commonly from reusing needles, inadequate stopper disinfection, or introducing the needle before alcohol evaporates. Peptide aggregation results from temperature excursions above 8°C or mechanical agitation during reconstitution. Particulate contamination occurs when using dull or barbed needles that shear rubber fragments from the stopper. Cloudy solutions are compromised and must be discarded.

ARA-290’s 11-amino-acid structure makes it more vulnerable to mechanical stress and temperature fluctuation than larger peptides with 30+ amino acids. Larger peptides have structural redundancy — losing a few bonds doesn’t necessarily destroy function. Short sequences like ARA-290 have no margin for error: a single disulfide bond disruption or backbone hydrolysis event can eliminate biological activity entirely. This demands stricter temperature control (2–8°C throughout), gentler mixing technique (no shaking or direct injection onto powder), and faster handling (minimize time outside refrigeration).

Stop shaking immediately and place the vial upright in the refrigerator at 2–8°C. Allow it to sit undisturbed for at least 30 minutes — foam and bubbles created by shaking will settle as air escapes and the peptide re-equilibrates. Shaking introduces oxidative stress at the air-liquid interface and creates mechanical shear that denatures a portion of the peptide, but most of the material remains viable if you stop quickly. For critical research endpoints, consider this vial partially compromised and reconstitute a fresh vial using correct technique.

No — reconstituted ARA-290 must be stored at 2–8°C to prevent irreversible degradation. Temperature excursions above 8°C cause transient unfolding, where the peptide partially denatures and then refolds incorrectly when returned to refrigeration. Even brief warm exposure (5–10 minutes) reduces effective peptide concentration by 10–15%, and one hour at room temperature can reduce potency by 15–30%. Once denatured, peptides cannot be restored by re-cooling — the structural damage is permanent.

The three most common errors are: (1) injecting bacteriostatic water directly onto the lyophilised powder instead of down the vial wall, creating mechanical shear denaturation; (2) leaving the vial at room temperature during handling instead of maintaining 2–8°C throughout, causing transient unfolding; (3) failing to equalize pressure before withdrawing the needle, pulling contaminants back into the vial on every subsequent draw. These errors produce inconsistent results across batches even when using identical peptides from the same supplier — the peptide quality is fine, but handling technique isn’t.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA